Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

PLUS-IS-LESS project: Procalcitonin and Lung UltraSonography-based antibiotherapy in patients with Lower rESpiratory tract infection in Swiss Emergency Departments: study protocol for a pragmatic stepped-wedge cluster-randomized trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Corporate Authors:
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central, 2006-
    • الموضوع:
    • نبذة مختصرة :
      Background: Lower respiratory tract infections (LRTIs) are among the most frequent infections and a significant contributor to inappropriate antibiotic prescription. Currently, no single diagnostic tool can reliably identify bacterial pneumonia. We thus evaluate a multimodal approach based on a clinical score, lung ultrasound (LUS), and the inflammatory biomarker, procalcitonin (PCT) to guide prescription of antibiotics. LUS outperforms chest X-ray in the identification of pneumonia, while PCT is known to be elevated in bacterial and/or severe infections. We propose a trial to test their synergistic potential in reducing antibiotic prescription while preserving patient safety in emergency departments (ED).
      Methods: The PLUS-IS-LESS study is a pragmatic, stepped-wedge cluster-randomized, clinical trial conducted in 10 Swiss EDs. It assesses the PLUS algorithm, which combines a clinical prediction score, LUS, PCT, and a clinical severity score to guide antibiotics among adults with LRTIs, compared with usual care. The co-primary endpoints are the proportion of patients prescribed antibiotics and the proportion of patients with clinical failure by day 28. Secondary endpoints include measurement of change in quality of life, length of hospital stay, antibiotic-related side effects, barriers and facilitators to the implementation of the algorithm, cost-effectiveness of the intervention, and identification of patterns of pneumonia in LUS using machine learning.
      Discussion: The PLUS algorithm aims to optimize prescription of antibiotics through improved diagnostic performance and maximization of physician adherence, while ensuring safety. It is based on previously validated tests and does therefore not expose participants to unforeseeable risks. Cluster randomization prevents cross-contamination between study groups, as physicians are not exposed to the intervention during or before the control period. The stepped-wedge implementation of the intervention allows effect calculation from both between- and within-cluster comparisons, which enhances statistical power and allows smaller sample size than a parallel cluster design. Moreover, it enables the training of all centers for the intervention, simplifying implementation if the results prove successful. The PLUS algorithm has the potential to improve the identification of LRTIs that would benefit from antibiotics. When scaled, the expected reduction in the proportion of antibiotics prescribed has the potential to not only decrease side effects and costs but also mitigate antibiotic resistance.
      Trial Registration: This study was registered on July 19, 2022, on the ClinicalTrials.gov registry using reference number: NCT05463406.
      Trial Status: Recruitment started on December 5, 2022, and will be completed on November 3, 2024. Current protocol version is version 3.0, dated April 3, 2023.
      (© 2024. The Author(s).)
    • References:
      J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686)
      JAMA. 1997 Nov 5;278(17):1440-5. (PMID: 9356004)
      Clin Infect Dis. 2017 Jul 15;65(2):183-190. (PMID: 28407054)
      Curr Probl Diagn Radiol. 2017 Jul - Aug;46(4):305-316. (PMID: 28185691)
      BMJ. 2014 Mar 07;348:g1687. (PMID: 24609605)
      J Ultrasound. 2021 Mar;24(1):57-65. (PMID: 32266687)
      Eur J Emerg Med. 2018 Oct;25(5):312-321. (PMID: 29189351)
      BMC Infect Dis. 2014 Jun 17;14:335. (PMID: 24938861)
      Arch Intern Med. 2008 Oct 13;168(18):2000-7; discussion 2007-8. (PMID: 18852401)
      N Engl J Med. 2018 Jul 19;379(3):236-249. (PMID: 29781385)
      J Emerg Med. 2019 Jan;56(1):53-69. (PMID: 30314929)
      Ann Intern Med. 2019 Aug 6;171(3):153-163. (PMID: 31284301)
      Neth J Med. 2014 Apr;72(3):170-8. (PMID: 24846935)
      Lancet. 2004 Feb 21;363(9409):600-7. (PMID: 14987884)
      Intensive Care Med. 2012 Apr;38(4):577-91. (PMID: 22392031)
      BMJ Open Respir Res. 2014 Jul 08;1(1):e000038. (PMID: 25478185)
      Pneumonia (Nathan). 2018 Dec 25;10:15. (PMID: 30603378)
      Int J Emerg Med. 2018 Mar 12;11(1):8. (PMID: 29527652)
      J Intern Med. 2015 Aug;278(2):193-202. (PMID: 25597400)
      Biometrics. 2020 Sep;76(3):951-962. (PMID: 31625596)
      BMJ. 2009 May 05;338:b1374. (PMID: 19416992)
      Stat Med. 2003 Jan 30;22(2):169-86. (PMID: 12520555)
      J Clin Epidemiol. 2013 Jul;66(7):752-8. (PMID: 23523551)
      BMC Health Serv Res. 2007 Jul 05;7:102. (PMID: 17615073)
      Clin Microbiol Infect. 2011 Nov;17 Suppl 6:E1-59. (PMID: 21951385)
      J Clin Epidemiol. 2016 Jan;69:137-46. (PMID: 26344808)
      BMJ. 2021 Sep 21;374:n2132. (PMID: 34548312)
      BMC Pulm Med. 2019 Aug 6;19(1):143. (PMID: 31387559)
      Clin Microbiol Infect. 2018 Nov;24(11):1158-1163. (PMID: 29447989)
      BMJ. 2013 Jan 08;346:e7586. (PMID: 23303884)
      JAMA. 2019 Jan 15;321(2):139-140. (PMID: 30589917)
      JAMA Intern Med. 2019 Aug 01;179(8):1052-1060. (PMID: 31282921)
      Respir Res. 2014 Apr 23;15:50. (PMID: 24758612)
      PLOS Digit Health. 2023 Jul 17;2(7):e0000108. (PMID: 37459285)
      Eur Respir Rev. 2016 Jun;25(140):178-88. (PMID: 27246595)
      BMJ. 2010 May 18;340:c2096. (PMID: 20483949)
      J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660)
      Am J Respir Crit Care Med. 2015 Oct 15;192(8):974-82. (PMID: 26168322)
      JAMA. 2009 Sep 9;302(10):1059-66. (PMID: 19738090)
      Arch Intern Med. 2012 May 14;172(9):715-22. (PMID: 22782201)
      PLoS One. 2016 Feb 26;11(2):e0149895. (PMID: 26918859)
      BMJ. 2013 Apr 30;346:f2450. (PMID: 23633005)
      JAMA. 2012 May 2;307(17):1801-2. (PMID: 22492759)
      Infect Drug Resist. 2019 Dec 20;12:3903-3910. (PMID: 31908502)
    • Grant Information:
      33IC30_201300 / 1 Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
    • Contributed Indexing:
      Investigator: N Boillat-Blanco; WC Albrich; N Garin; B Mattsson; S Gasser; D Von Ow
      Keywords: Algorithm; Antibiotic prescription; Clinical trial; Community-acquired pneumonia; Diagnostic tool; Emergency department; Lower respiratory tract infection; Lung ultrasound; Procalcitonin; Protocol
    • Molecular Sequence:
      ClinicalTrials.gov NCT05463406
    • الرقم المعرف:
      0 (Procalcitonin)
      0 (Anti-Bacterial Agents)
    • الموضوع:
      Date Created: 20240125 Date Completed: 20240129 Latest Revision: 20241023
    • الموضوع:
      20241023
    • الرقم المعرف:
      PMC10809691
    • الرقم المعرف:
      10.1186/s13063-023-07795-y
    • الرقم المعرف:
      38273319